Suppr超能文献

基于正电子发射断层扫描(PET)的临床肿瘤个性化管理:可预见未来的必由之路。

PET-Based Personalized Management in Clinical Oncology: An Unavoidable Path for the Foreseeable Future.

作者信息

Basu Sandip, Alavi Abass

机构信息

Radiation Medicine Centre, Bhabha Atomic Research Centre, Tata Memorial Hospital Annexe, Jerbai Wadia Road, Parel, Mumbai 400 012, India.

Division of Nuclear Medicine, Perelman School of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.

出版信息

PET Clin. 2016 Jul;11(3):203-7. doi: 10.1016/j.cpet.2016.03.002. Epub 2016 May 2.

Abstract

It is imperative that the thrust of clinical practice in the ensuing years would be to develop personalized management model for various disorders. PET-computed tomography (PET-CT) based molecular functional imaging has been increasingly utilized for assessment of tumor and other nonmalignant disorders and has the ability to explore disease phenotype on an individual basis and address critical clinical decision making questions related to practice of personalized medicine. Hence, it is essential to make a concerted systematic effort to explore and define the appropriate place of PET-CT in personalized clinical practice in each of malignancies, which would strengthen the concept further. The potential advantages of PET based disease management can be classified into broad categories: (1) Traditional: which includes assessment of disease extent such as initial disease staging and restaging, treatment response evaluation particularly early in the course and thus PET-CT response adaptive decision for continuing the same regimen or switching to salvage schedules; there has been continuous addition of newer application of PET based disease restaging in oncological parlance (eg, Richter transformation); (2) Recent and emerging developments: this includes exploring tumor biology with FDG and non-FDG PET tracers. The potential of multitracer PET imaging (particularly new and novel tracers, eg, 68Ga-DOTA-TOC/NOC/TATE in NET, 68Ga-PSMA and 18F-fluorocholine in prostate carcinoma, 18F-fluoroestradiol in breast carcinoma) has provided a scientific basis to stratify and select appropriate targeted therapies (both radionuclide and nonradionuclide treatment), a major boost for individualized disease management in clinical oncology. Integrating the molecular level information obtained from PET with structural imaging further individualizing treatment plan in radiation oncology, precision of interventions and biopsies of a particular lesion and forecasting disease prognosis.

摘要

在接下来的几年里,临床实践的重点必须是为各种疾病开发个性化管理模式。基于正电子发射断层扫描-计算机断层扫描(PET-CT)的分子功能成像已越来越多地用于评估肿瘤和其他非恶性疾病,并且有能力在个体基础上探索疾病表型,并解决与个性化医疗实践相关的关键临床决策问题。因此,必须齐心协力、系统地努力探索并确定PET-CT在每种恶性肿瘤的个性化临床实践中的适当位置,这将进一步强化这一概念。基于PET的疾病管理的潜在优势可大致分为两类:(1)传统优势:包括评估疾病范围,如初始疾病分期和再分期、治疗反应评估,特别是在病程早期,从而根据PET-CT反应做出适应性决策,以继续相同的治疗方案或改用挽救方案;在肿瘤学领域,基于PET的疾病再分期的新应用不断增加(例如, Richter转化);(2)最新和新兴发展:这包括用氟代脱氧葡萄糖(FDG)和非FDG PET示踪剂探索肿瘤生物学。多示踪剂PET成像的潜力(特别是新型和新颖的示踪剂,例如,用于神经内分泌肿瘤的68Ga-DOTA-TOC/NOC/TATE、用于前列腺癌的68Ga-PSMA和18F-氟胆碱、用于乳腺癌的18F-氟雌二醇)为分层和选择合适的靶向治疗(放射性核素和非放射性核素治疗)提供了科学依据,这对临床肿瘤学中的个体化疾病管理是一个重大推动。将从PET获得的分子水平信息与结构成像相结合,可进一步在放射肿瘤学中个性化治疗方案、提高特定病变干预和活检的精确性并预测疾病预后。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验